CAR-T news — June 2017

“One of the leading CAR T-cells immunotherapy company, Cellectis dosed the first blood cancer patient with the allogeneic, “off-the-shelf” CAR-T therapy, UCART123 at Weill Cornell Medicine and NewYork-Presbyterian Hospital…”

Scientists Get Closer to First CAR T-Cells Based Immunotherapy for Humans

Cellectis’ off-the-shelf CAR-T Cancer Therapy has Entered the Clinic

Cellectis’ Press Release…

First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital | Cellectis


A journalist from Bloomberg News is working on a story similar to the one below:

For experimental cancer therapy, a struggle to ensure supply keeps up with demand | Science | AAAS


“The sky-high cost of producing CAR T cells, and limitations on the availability and regulatory qualification of reagents can be barriers to making CAR T cell therapy accessible…”

Biotechin.Asia- Driving CAR T-Cell Therapy From Bench to Bedside

CAR-T Value Calculation In The Firing Line | Seeking Alpha


Work continues on applying CAR-T to solid tumors:

Unleashing CAR-T Therapies on Solid Tumors: Are We There Yet? | BIOtechNow

Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine’s Next Frontier – Celyad (NASDAQ:CYAD) | Seeking Alpha


A history of all reported deaths (clinically described as a “Grade 5 Adverse Event”) thus far from CAR-T:

EP Vantage – Spotlight – Putting a number on CAR-T deaths


Neurotoxicity needs separate treatment from CRS in CAR T-cell therapy  | (Free registration required)


Engineering CAR-T cells


CAR-T coverage in PC Magazine(!)

How Scientists Are Hacking Cancer | News & Opinion | PCMag.com

Upcoming CAR-T coverage at Bloomberg News?

For anyone who would like to share their stories of how they were able to gain access to CAR-T therapy, or whether they are still waiting to gain access…

I received the email below a few days ago from one of the lymphoma Yahoo Groups I am a member of. I’ve since shared my CAR-T story with Michelle, but my story may be less relevant than some of yours, since I did CAR-T way back in 2015. 🙂

Please read Michelle’s email below and see if you may be interested:

Hi. I’m a journalist at Bloomberg News, and I’m writing a story about Car-T therapy for DLBCL. I am hoping to find a patient who is willing to share their story and perspective about trying to get into one of the studies or is waiting for the therapy to be approved. We and others have written about the actual treatment and how that process occurs. I want to explore the issues that come with waiting for access, as that is likely to be a bigger issue once the approach is approved. I appreciate the help!

The story will have a US focus since the approval is supposed to come this year from the FDA. I am based in Minneapolis but can call anywhere to anyone, anytime. Thanks so much for any help!

Michelle Cortez
Email: mcortez@bloomberg.net
Phone: 612-991-8887

ICML 2017 – Prof. Stephen J. Schuster from the Abramson Cancer Center, Philadelphia, PA, US, discusses interim results from the phase II JULIET trial of CTL019 in adult patients with R/R DLBCL | LymphomaHub

Dr. Schuster details the entire process using Novartis’s CTL019 CAR-T at U. Penn.

http://www.lymphomahub.com/medical-information/prof-stephen-j-schuster-interim-results-of-the-juliet-trial-of-ctl019-in-rr-dlbcl-icml-2017

As a side note, my wife and I met with Dr. Schuster and his team for over 2 hours in February 2015. I found him to be a warm, down-to-earth doctor. I almost enrolled in his trial, before my wife happened to discover online that Memorial Sloan-Kettering in NYC, where I was already a patient, had just started enrolling Follicular Lymphoma patients in their CAR-T trial. (I’ve been told I’m fNHL patient #1 to complete CAR-T at MSK.)